Evidence map›Paper›PMID 39281224›Full record

ArticlePakistan journal of medical sciences2024

Mixture and Non-Mixture Cure Models for the survival analysis of SARS-CoV-2 patients in Khyber Pakhtunkhwa, Pakistan.

Naseem Asghar, Umair Khalil, Iftikhar Uddin

Abstract read
In one paragraph

Article in Pakistan journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Naseem AsgharNaseem Asghar, Lecturer, Department of Statistics, Abdul Wali Khan University Mardan, Pakistan.
Umair KhalilUmair Khalil, Associate Professor, Department of Statistics, Abdul Wali Khan University Mardan, Pakistan.
Iftikhar UddinIftikhar Uddin, Assistant Professor, Department of Community Medicine, Bacha Khan Medical College Mardan, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To examine the potential difference in survival and risk of death between asymptomatic and symptomatic SARS-CoV-2 patients, controlled by age and gender for all the attendance in hospitals of Khyber Pakhtunkhwa (KP), Pakistan. Methods: In this retrospective study, the medical records of 6273 SARS-CoV-2 patients admitted to almost all hospitals in Khyber Pakhtunkhwa during the first wave of the coronavirus outbreak from March to June 2020 were analysed. The effects of gender, age, and being symptomatic on the survival of SARS-CoV-2 patients were assessed using cure-survival models as opposed to the conventional Cox proportional hazards model. Results: The prevalence of initially symptomatic patients was 55.8%, and the overall mortality rate was 11.8%. The fitted cure-survival models suggest that age affects the probability of death (incidence) but not the short-term survival time of patients (latency); symptomatic patients have a higher risk of death than their asymptomatic counterparts, but the survival time of symptomatic patients is longer on average; gender has no significant effect on the probability of death and survival time. Conclusion: The available data and statistical results suggest that asymptomatic and young patients are generally less susceptible to initial infection with SARS-CoV-2 and therefore have a lower risk of death. Our regression models show that uncured asymptomatic patients generally have poorer short-term survival than their uncured symptomatic counterparts. The association between gender and survival outcome was not significant.

Indexed as

Cox proportional hazards modelKaplan-Meier curveMixture cure modelnon-mixture cure modelSARS-CoV-2

Identifiers

PMID39281224
PMCPMC11395337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.